鞘内巴氯芬治疗遗传性痉挛性截瘫:系统综述。

IF 1.5 4区 医学 Q3 REHABILITATION International Journal of Rehabilitation Research Pub Date : 2024-03-01 Epub Date: 2024-01-20 DOI:10.1097/MRR.0000000000000607
Luisa Viana Pinto, Isabel Romeiro, Filipa Gouveia, Joana Ramalho, Sara Ribeiro Silva, Maria Inês Táboas Simões, Joana Rodrigues Leal
{"title":"鞘内巴氯芬治疗遗传性痉挛性截瘫:系统综述。","authors":"Luisa Viana Pinto, Isabel Romeiro, Filipa Gouveia, Joana Ramalho, Sara Ribeiro Silva, Maria Inês Táboas Simões, Joana Rodrigues Leal","doi":"10.1097/MRR.0000000000000607","DOIUrl":null,"url":null,"abstract":"<p><p>This systematic review aims to evaluate the use of intrathecal baclofen (ITB) for hereditary spastic paraparesis (HSP) treatment. An extensive search in two electronical databases was performed. We identified articles published between 1990 and 2022 (PubMed, Scopus), and applied the following inclusion criteria: diagnosis of HSP at the time of the intervention, either familial or sporadic; report on the effect of ITB in patients with HSP; test trial via either bolus injections or continuous infusion tests; and ITB pump implantation. A data extraction sheet based on the Cochrane Consumers and Communication Review Group's data extraction template was created and adapted to collect relevant data. A qualitative analysis was performed to present the results in narrative summary fashion. A total of 6 studies met our inclusion criteria. 51 patients with HSP had a pre-implantation ITB trial. The time since the diagnosis until the pump implantation ranged from 5 to 30 years. The initial bolus ranged from 20 to 50 μg and the mean doses used at steady state ranged from 65 to 705 μg. An improvement in spasticity was observed on the modified Ashworth Scale in patients treated with ITB. Although all studies reported a subjective gait improvement, not all found an objective improvement in gait. The most common side effect reported was catheter-related problems. The findings of this review support the use of ITB as an effective and a viable option for the treatment of spasticity in HSP refractory to conservative therapies.</p>","PeriodicalId":14301,"journal":{"name":"International Journal of Rehabilitation Research","volume":null,"pages":null},"PeriodicalIF":1.5000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Intrathecal baclofen for the management of hereditary spastic paraparesis: a systematic review.\",\"authors\":\"Luisa Viana Pinto, Isabel Romeiro, Filipa Gouveia, Joana Ramalho, Sara Ribeiro Silva, Maria Inês Táboas Simões, Joana Rodrigues Leal\",\"doi\":\"10.1097/MRR.0000000000000607\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>This systematic review aims to evaluate the use of intrathecal baclofen (ITB) for hereditary spastic paraparesis (HSP) treatment. An extensive search in two electronical databases was performed. We identified articles published between 1990 and 2022 (PubMed, Scopus), and applied the following inclusion criteria: diagnosis of HSP at the time of the intervention, either familial or sporadic; report on the effect of ITB in patients with HSP; test trial via either bolus injections or continuous infusion tests; and ITB pump implantation. A data extraction sheet based on the Cochrane Consumers and Communication Review Group's data extraction template was created and adapted to collect relevant data. A qualitative analysis was performed to present the results in narrative summary fashion. A total of 6 studies met our inclusion criteria. 51 patients with HSP had a pre-implantation ITB trial. The time since the diagnosis until the pump implantation ranged from 5 to 30 years. The initial bolus ranged from 20 to 50 μg and the mean doses used at steady state ranged from 65 to 705 μg. An improvement in spasticity was observed on the modified Ashworth Scale in patients treated with ITB. Although all studies reported a subjective gait improvement, not all found an objective improvement in gait. The most common side effect reported was catheter-related problems. The findings of this review support the use of ITB as an effective and a viable option for the treatment of spasticity in HSP refractory to conservative therapies.</p>\",\"PeriodicalId\":14301,\"journal\":{\"name\":\"International Journal of Rehabilitation Research\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2024-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Rehabilitation Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/MRR.0000000000000607\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/20 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"REHABILITATION\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Rehabilitation Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/MRR.0000000000000607","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/20 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"REHABILITATION","Score":null,"Total":0}
引用次数: 0

摘要

本系统综述旨在评估鞘内巴氯芬(ITB)在遗传性痉挛性截瘫(HSP)治疗中的应用。我们在两个电子数据库中进行了广泛的检索。我们确定了 1990 年至 2022 年间发表的文章(PubMed、Scopus),并采用了以下纳入标准:干预时诊断为 HSP(家族性或散发性);关于 ITB 对 HSP 患者疗效的报告;通过栓剂注射或连续输注测试进行的试验;以及 ITB 泵植入。我们根据 Cochrane 消费者与沟通审查小组的数据提取模板制作并调整了数据提取表,以收集相关数据。我们进行了定性分析,以叙述总结的方式呈现结果。共有 6 项研究符合我们的纳入标准。51 名 HSP 患者接受了植入前 ITB 试验。从确诊到植入泵的时间从 5 年到 30 年不等。初始栓塞剂量从 20 微克到 50 微克不等,稳态时的平均剂量从 65 微克到 705 微克不等。根据改良的阿什沃斯量表,接受 ITB 治疗的患者痉挛状况有所改善。虽然所有研究都报告了主观步态的改善,但并非所有研究都发现了客观步态的改善。最常见的副作用是导管相关问题。本综述的研究结果支持使用 ITB 作为治疗保守疗法难治的 HSP 痉挛的一种有效且可行的方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Intrathecal baclofen for the management of hereditary spastic paraparesis: a systematic review.

This systematic review aims to evaluate the use of intrathecal baclofen (ITB) for hereditary spastic paraparesis (HSP) treatment. An extensive search in two electronical databases was performed. We identified articles published between 1990 and 2022 (PubMed, Scopus), and applied the following inclusion criteria: diagnosis of HSP at the time of the intervention, either familial or sporadic; report on the effect of ITB in patients with HSP; test trial via either bolus injections or continuous infusion tests; and ITB pump implantation. A data extraction sheet based on the Cochrane Consumers and Communication Review Group's data extraction template was created and adapted to collect relevant data. A qualitative analysis was performed to present the results in narrative summary fashion. A total of 6 studies met our inclusion criteria. 51 patients with HSP had a pre-implantation ITB trial. The time since the diagnosis until the pump implantation ranged from 5 to 30 years. The initial bolus ranged from 20 to 50 μg and the mean doses used at steady state ranged from 65 to 705 μg. An improvement in spasticity was observed on the modified Ashworth Scale in patients treated with ITB. Although all studies reported a subjective gait improvement, not all found an objective improvement in gait. The most common side effect reported was catheter-related problems. The findings of this review support the use of ITB as an effective and a viable option for the treatment of spasticity in HSP refractory to conservative therapies.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
3.10
自引率
0.00%
发文量
88
审稿时长
6-12 weeks
期刊介绍: International Journal of Rehabilitation Research is a quarterly, peer-reviewed, interdisciplinary forum for the publication of research into functioning, disability and contextual factors experienced by persons of all ages in both developed and developing societies. The wealth of information offered makes the journal a valuable resource for researchers, practitioners, and administrators in such fields as rehabilitation medicine, outcome measurement nursing, social and vocational rehabilitation/case management, return to work, special education, social policy, social work and social welfare, sociology, psychology, psychiatry assistive technology and environmental factors/disability. Areas of interest include functioning and disablement throughout the life cycle; rehabilitation programmes for persons with physical, sensory, mental and developmental disabilities; measurement of functioning and disability; special education and vocational rehabilitation; equipment access and transportation; information technology; independent living; consumer, legal, economic and sociopolitical aspects of functioning, disability and contextual factors.
期刊最新文献
The mediating role of kinesiophobia in pain intensity, physical function, and physical activity level in inflammatory arthritis. Technology for helping people with neuromotor, intellectual, and speech disabilities engage in leisure and communication activities: a proof-of-concept study. Efficacy of continuous passive motion compared to physiotherapy in rehabilitation after total knee replacement: a prospective randomized controlled non-inferiority trial. Understanding the multidimensionality of a concern for falling in people with unilateral transtibial amputation: a cross-sectional study. Responsiveness of the Australian Spasticity Assessment Scale to botulinum neurotoxin injection into spastic wrist flexors after acquired brain injury.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1